| Centers Home Health Care Of Otsego | |
| 128 Phoenix Mills Cross Road, Cooperstown, New York 13326 | |
| (607) 544-2667 | |
| Name | Centers Home Health Care Of Otsego |
|---|---|
| Location | 128 Phoenix Mills Cross Road, Cooperstown, New York |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 337054 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 12116, 12155, 12197, 13315, 13320, 13326, 13335, 13348, 13439, 13468, 13491, 13807, 13808, 13810, 13820, 13825, 13834, 13849 |
| NPI Number | 1255848305 |
| Organization Name | OTSEGO SNF OPERATIONS ASSOC LLC |
| Doing Business As | CENTERS HOME HEALTH CARE OF OTSEGO |
| Address | 128 Phoenix Mills Rd, Cooperstown, NY 13326 |
| Phone Number | 607-544-2600 |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
| NPI Number | 1407250012 |
| Organization Name | CCRN OPERATOR LLC |
| Doing Business As | FOCUS HOME CARE AT OTSEGO |
| Address | 128 Phoenix Mills Rd, Cooperstown, NY 13326 |
| Phone Number | 607-544-2600 |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
| Quality Rating: |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 76.2 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 93.2 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 92.9 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 61 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 87.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 84.6 | 96.4 |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 79.2 | 79.6 |
| How often patients got better at getting in and out of bed | 81.8 | 81.1 |
| How often patients got better at bathing | 67.6 | 82.3 |
| How often patients’ breathing improved | 54.8 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 64.5 | 75 |
| How often home health patients had to be admitted to the hospital | 18.1 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 18.7 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97 | 94 |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | Not Available |
| Health team communicated well with them | Not Available |
| Health team discussed medicines, pain, and home safety | Not Available |
| How patients rated overall care from agency | Not Available |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
The patient survey data of Centers Home Health Care Of Otsego is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 88 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 78 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 95 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 82 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 79 | 78 |
News Archive
The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Nearly 50 percent of recently-deployed Soldiers who sustained a mild traumatic brain injury reported post-concussive symptoms - like headaches, sleep disturbance, and forgetfulness - three months after returning from deployment, according to a study published March 17 in Neurology by researchers at the Uniformed Services University of the Health Sciences (USU), and the Defense and Veterans Brain Injury Center.
› Verified 8 days ago
Centers Home Health Care Of Otsego Location: 128 Phoenix Mills Cross Road, Cooperstown, New York 13326 Ratings: Phone: (607) 544-2667 |